CervoMed (CRVO) vs Immutep (IMMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immutep (IMMP) has outperformed CervoMed (CRVO) over the past year, gaining 80.8% versus a loss of 83.6%. Over five years, IMMP leads with a -8.5% price change compared with -95.0% for CRVO. Immutep is the larger company by market cap ($22.9 million vs $22.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | IMMP |
|---|---|---|
| Share price | $1.46 | $3.11 |
| Market cap | $22.09M | $22.92M |
| 1-day change | +9.77% | -9.06% |
| YTD return | -81.52% | +8.74% |
| 1-year return | -83.56% | +80.81% |
| 5-year return | -95.01% | -8.53% |
| EPS (TTM) | $-2.65 | $-7.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.01M | — |
| Revenue growth (YoY) | -58.86% | — |
| Net income (latest FY) | $-26.97M | — |
| Operating margin | -706.22% | — |
| Net margin | -673.06% | — |
| 52-week high | $10.00 | $70.60 |
| 52-week low | $1.27 | $2.66 |
| Distance from 52-week high | -85.40% | -95.59% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +954.79% | +864.63% |
| Average volume | 489.10K | 26.07K |
| Shares outstanding | 15.13M | 7.37M |
| Employees | 15 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed CRVO by 164.4 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
CRVO vs IMMP FAQ
Which is bigger, CervoMed or Immutep?
Immutep (IMMP) is larger, with a market capitalization of $22.92M compared with $22.09M for CervoMed (CRVO).
Which stock has performed better over the past year, CRVO or IMMP?
IMMP returned +80.81% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Immutep in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.